Expansion of pharmaceutical intermediate product line with multiple new high-purity offerings

ENTAI TRADING announced in 2025 that it has significantly expanded its pharmaceutical intermediate product line, introducing multiple new high-purity intermediates with purity levels exceeding 99.9%, meeting the stringent requirements of premium pharmaceutical clients.

The newly added products are primarily applied in the fields of anti-tumor drugs, antiviral drugs, cardiovascular drugs, antibiotics, and more. Product categories include amino acid derivatives, heterocyclic compounds, chiral intermediates, protected amino acids, and others, totaling over 30 varieties.

All newly added products undergo rigorous quality testing, meeting or exceeding pharmacopoeia standards for purity. Our facility is equipped with advanced analytical instruments—including HPLC, GC, and NMR—to ensure consistent, reliable quality for every batch.

In anticancer drug intermediates, the company has added several key intermediates for targeted therapies. These products have passed supplier audits by multiple international pharmaceutical companies and are available for stable supply to innovator drug developers.

Chiral intermediates are a key product in this expansion. With growing demand for chiral drugs in the pharmaceutical industry, the company has introduced advanced chiral synthesis and separation technologies to provide high enantiomeric excess (ee > 99%) chiral intermediate products.

ENTAI TRADING's Product Director stated: "Pharmaceutical intermediates are a core focus of our strategic development. This product line expansion marks a significant advancement in our technical capabilities and supply capacity for high-purity pharmaceutical intermediates. We will continue to collaborate closely with global pharmaceutical companies to deliver high-quality intermediate products for innovative drug development."

All newly added products are stocked with safety inventory to rapidly fulfill customer orders. The company also offers custom synthesis services to develop pharmaceutical intermediates tailored to specific customer requirements.